Overview

Tranexamic Acid Dosage for Topical Treatment of Anterior Epistaxis

Status:
Completed
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
Patients with epistaxis usually apply to the emergency department for initial treatment. According to recent research, tranexamic acid is effective in the treatment of epistaxis. The research compare the therapeutic superiority of saline with 500 and 1000 mg doses of topical tranexamic acid in the treatment of anterior epistaxis. The design of the phase 4 clinical trial was randomized controlled double-blind. A total of 152 cases in 3 groups were included in the study. Group 1 was treated with 1000 mg of tranexamic acid, group 2 with 500 mg of tranexamic acid, and group 3 with saline. The primary outcome of the study was bleeding control at the 5th and 10th minutes. Secondary outcomes were determined as the need for salvage therapy, recurrent bleeding within 24 hours, the presence of side effects, and the need for otorhinolaryngology consultation.
Phase:
Phase 4
Details
Lead Sponsor:
Izmir Ataturk Training and Research Hospital
Treatments:
Tranexamic Acid